Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study). Issue 8 (31st May 2015)

• Record Type: Journal Article
• Authors: Rosenstock, J.; Hollander, P.; Bhargava, A.; Ilag, L. L.; Pollom, R. K.; Zielonka, J. S.; Huster, W. J.; Prince, M. J.
• Is Part Of: Diabetes, obesity & metabolism. Volume 17:Issue 8(2015:Aug.)
• Page Start: 734
• Page End: 741
• Publication Date: 2015-05-31
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12482
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main" id="dom12482-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="dom12482-sec-0001" sec-type="section"> <title>Aims</title> <p id="dom12482-para-0001">To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) and the reference product (Lantus®) insulin glargine (IGlar) in combination with oral antihyperglycaemic medications in patients with type 2 diabetes (T2D).</p> </sec> <sec id="dom12482-sec-0002" sec-type="section"> <title>Methods</title> <p id="dom12482-para-0002">This phase III, randomized, double‐blind, 24‐week study enrolled patients with T2D who were insulin‐naïve [glycated haemoglobin (HbA1c) ≥7 and ≤11.0%] or previously on IGlar (HbA1c ≤11%) and treated with ≥2 oral antihyperglycaemic medications. Patients were randomized to receive once‐daily LY IGlar (n = 376) or IGlar (n = 380) for 24 weeks. The primary efficacy outcome was to test the non‐inferiority (0.4% and then 0.3% margin) of LY IGlar to IGlar, as measured by change in HbA1c from baseline to 24 weeks.</p> </sec> <sec id="dom12482-sec-0003" sec-type="section"> <title>Results</title> <p id="dom12482-para-0003">Both treatment groups had similar and significant (p < 0.001) within‐group decreases in mean HbA1c values from baseline. LY IGlar met non‐inferiority criteria compared with IGlar for change in HbA1c from baseline [−1.29 vs −1.34%; respectively, least‐squares mean difference 0.052% (95% confidence interval −0.070 to 0.175); p > 0.05]. There were no treatment differences (p > 0.05) in fasting plasma glucose, proportion of patients reaching HbA1c <7% or insulin dose at 24 weeks. Adverse events, allergic reactions, weight change, hypoglycaemia and insulin antibodies were similar between treatment groups. Similar findings were observed in patients who were insulin‐naïve or previously treated with IGlar at baseline.</p> </sec> <sec id="dom12482-sec-0004" sec-type="section"> <title>Conclusions</title> <p id="dom12482-para-0004">Both LY IGlar and IGlar, when used in combination with oral antihyperglycaemic medications, provided effective and similar glucose control with similar safety profiles in patients with T2D.</p> </sec> </abstract>